SCHEMBL25757310

SCHEMBL25757310

COc1nc(CN2C(=O)c3ccccc3C2=O)ccc1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 1/20 0.47
PKM P14618 1/20 0.47
TYR P14679 2/20 0.45
RECQL P46063 2/20 0.45
MAPT P10636 1/20 0.45
KDM4E B2RXH2 2/20 0.44
LMNA P02545 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP1B1 Q16678 3/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 2/20 0.43
HPGD P15428 1/20 0.43
GAA P10253 2/20 0.42
RPS6KA2 Q15349 1/20 0.42
RXFP1 Q9HBX9 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30498392 1.00 MEN1 (0.47) MEN1KMT2AALDH1A1PKMTYR
SCHEMBL8218007 0.80 ALDH1A1 (0.51) MEN1KMT2AALDH1A1PKMTYR
SCHEMBL29838014 0.78 MEN1 (0.50) MEN1KMT2AALDH1A1PKMTYR
SCHEMBL26693814 0.78 MEN1 (0.50) MEN1KMT2AALDH1A1PKMTYR
SCHEMBL18137619 0.75 KMT2A (0.44) MEN1KMT2AALDH1A1PKMTYR
SCHEMBL8377843 0.73 ALDH1A1 (0.68) MEN1KMT2AALDH1A1PKMTYR
SCHEMBL2766815 0.73 MEN1 (0.58) MEN1KMT2AALDH1A1PKMTYR
SCHEMBL38652361 0.73 MEN1 (0.58) MEN1KMT2AALDH1A1PKMTYR
SCHEMBL22981697 0.73 CASP3 (0.48) MEN1KMT2AALDH1A1PKMKDM4E
SCHEMBL13348984 0.73 KDM4E (0.49) MEN1KMT2AALDH1A1PKMRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MEN1 2298/4885KMT2A 242/4885ALDH1A1 4805/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MEN1 2298/4885KMT2A 242/4885ALDH1A1 4805/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 MEN1 2298/4885KMT2A 242/4885ALDH1A1 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.